Business Context and Reporting Period
This Form 8-K is filed by Obalon Therapeutics, Inc. (not Vyome Holdings, Inc., as noted in the metadata request) on May 12, 2021. The filing serves to report the Company's financial results for the three months ended March 31, 2021. The Company is incorporated in Delaware and its common stock trades on the NASDAQ Capital Market under the symbol OBLN. The registrant is classified as an emerging growth company.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the press release furnished as Exhibit 99.1, which is not included in the input text.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. It only confirms that results for the quarter ended March 31, 2021, have been reported.
Guidance, Outlook, and Risks
The text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It explicitly states that the information furnished (including the press release) is not deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings.
Investor Verification Checklist
- Verify the correct registrant name: The filing is for Obalon Therapeutics, Inc., not Vyome Holdings, Inc.
- Review Exhibit 99.1 (Press Release dated May 12, 2021) for actual financial figures, as they are absent from this 8-K cover sheet.
- Confirm the reporting period covers the three months ended March 31, 2021.
- Note that the press release information is furnished but not "filed" under Section 18 of the Exchange Act.